The following are the top rated Healthcare stocks according to Validea's Small-Cap Growth Investor model based on the published strategy of Motley Fool. This strategy looks for small cap growth stocks with solid fundamentals and strong price performance.
CHINA BIOLOGIC PRODUCTS HOLDINGS INC (CBPO) is a mid-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Motley Fool is 79% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: China Biologic Products Holdings, Inc. is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products in China. It operates through the manufacture and sales of human plasma products segment. China Biologic has a product portfolio with over 20 various dosage forms of plasma products and other biopharmaceutical products across nine categories.The Company's products include human albumin, human immunoglobulin, immunoglobulin for intravenous injection (IVIG), human hepatitis B immunoglobulin, human rabies immunoglobulin, human tetanus immunoglobulin, placenta polypeptide, Factor VIII and human prothrombin complex concentrate (PCC).
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
| PROFIT MARGIN: | PASS |
| RELATIVE STRENGTH: | FAIL |
| COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: | PASS |
| INSIDER HOLDINGS: | PASS |
| CASH FLOW FROM OPERATIONS: | PASS |
| PROFIT MARGIN CONSISTENCY: | PASS |
| R&D AS A PERCENTAGE OF SALES: | PASS |
| CASH AND CASH EQUIVALENTS: | PASS |
| INVENTORY TO SALES: | PASS |
| ACCOUNTS RECEIVABLE TO SALES: | PASS |
| LONG TERM DEBT/EQUITY RATIO: | PASS |
| "THE FOOL RATIO" (P/E TO GROWTH): | FAIL |
| AVERAGE SHARES OUTSTANDING: | PASS |
| SALES: | FAIL |
| DAILY DOLLAR VOLUME: | PASS |
| PRICE: | PASS |
| INCOME TAX PERCENTAGE: | FAIL |
Detailed Analysis of CHINA BIOLOGIC PRODUCTS HOLDINGS INC
ZYNEX INC. (ZYXI) is a small-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Motley Fool is 79% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Zynex, Inc. manufactures and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. The Company operates through medical devices segment, which include electrotherapy and pain management products. The Company conducts its business through its subsidiaries and the operating subsidiary is Zynex Medical, Inc. (ZMI). The Company's devices are intended for pain management to reduce reliance on drugs and provide rehabilitation and mobility through the utilization of non-invasive muscle stimulation, electromyography technology, interferential current (IFC), neuromuscular electrical stimulation (NMES) and transcutaneous electrical nerve stimulation (TENS). The Company's devices are small, portable, battery-operated and include an electrical pulse generator that is connected to the body via electrodes.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
| PROFIT MARGIN: | PASS |
| RELATIVE STRENGTH: | PASS |
| COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: | PASS |
| INSIDER HOLDINGS: | PASS |
| CASH FLOW FROM OPERATIONS: | PASS |
| PROFIT MARGIN CONSISTENCY: | FAIL |
| R&D AS A PERCENTAGE OF SALES: | NEUTRAL |
| CASH AND CASH EQUIVALENTS: | PASS |
| INVENTORY TO SALES: | PASS |
| ACCOUNTS RECEIVABLE TO SALES: | PASS |
| LONG TERM DEBT/EQUITY RATIO: | PASS |
| "THE FOOL RATIO" (P/E TO GROWTH): | FAIL |
| AVERAGE SHARES OUTSTANDING: | PASS |
| SALES: | PASS |
| DAILY DOLLAR VOLUME: | FAIL |
| PRICE: | PASS |
| INCOME TAX PERCENTAGE: | FAIL |
Detailed Analysis of ZYNEX INC.
RETRACTABLE TECHNOLOGIES, INC. (RVP) is a small-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Motley Fool is 76% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Retractable Technologies, Inc. designs, develops and manufactures safety medical products for the healthcare industry. The Company markets VanishPoint and PatientSafe products. The VanishPoint products are designed specifically to prevent needle stick injuries and to prevent reuse. The VanishPoint safety products include tuberculin, insulin and allergy antigen VanishPoint syringes; 0.5mL, 1mL, 2mL, 3mL, 5mL and 10mL VanishPoint syringes, and the VanishPoint autodisable syringe. It also sells the VanishPoint intravenous catheter, the VanishPoint blood collection tube holder and the VanishPoint blood collection set. The PatientSafe syringe reduces the risk of bloodstream infections resulting from catheter hub contamination. Its PatientSafe products include 3mL, 5mL, 10mL, 20mL, 30mL and 60mL syringes, and the PatientSafe Luer cap. Its product designs include retractable needle syringe designs, retractable needle designs and retractable needle dental syringe designs.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
| PROFIT MARGIN: | PASS |
| RELATIVE STRENGTH: | PASS |
| COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: | FAIL |
| INSIDER HOLDINGS: | PASS |
| CASH FLOW FROM OPERATIONS: | PASS |
| PROFIT MARGIN CONSISTENCY: | PASS |
| R&D AS A PERCENTAGE OF SALES: | NEUTRAL |
| CASH AND CASH EQUIVALENTS: | PASS |
| INVENTORY TO SALES: | PASS |
| ACCOUNTS RECEIVABLE TO SALES: | PASS |
| LONG TERM DEBT/EQUITY RATIO: | FAIL |
| "THE FOOL RATIO" (P/E TO GROWTH): | FAIL |
| AVERAGE SHARES OUTSTANDING: | PASS |
| SALES: | PASS |
| DAILY DOLLAR VOLUME: | PASS |
| PRICE: | PASS |
| INCOME TAX PERCENTAGE: | FAIL |
Detailed Analysis of RETRACTABLE TECHNOLOGIES, INC.
USANA HEALTH SCIENCES, INC. (USNA) is a small-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Motley Fool is 76% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: USANA Health Sciences, Inc. develops and manufactures science-based nutritional and personal care products. The Company operates as a direct selling company in two geographic regions: Americas and Europe, and Asia Pacific, which includes three sub-regions: Southeast Asia Pacific, Greater China and North Asia. Its product lines include USANA Nutritionals Essentials, Optimizers, Foods, Sense-beautiful science and All Other. Its USANA Nutritionals Essentials product line includes vitamin and mineral supplements that provide a foundation of total body nutrition for every age group beginning with children of approximately one year. Its Optimizers product line consists of targeted supplements designed to meet individual health and nutritional needs. Its Sense-beautiful science product line includes science-based, personal care products that support skin and hair by providing topical nourishment, moisturization and protection.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
| PROFIT MARGIN: | PASS |
| RELATIVE STRENGTH: | FAIL |
| COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: | FAIL |
| INSIDER HOLDINGS: | PASS |
| CASH FLOW FROM OPERATIONS: | PASS |
| PROFIT MARGIN CONSISTENCY: | PASS |
| R&D AS A PERCENTAGE OF SALES: | PASS |
| CASH AND CASH EQUIVALENTS: | PASS |
| INVENTORY TO SALES: | PASS |
| ACCOUNTS RECEIVABLE TO SALES: | PASS |
| LONG TERM DEBT/EQUITY RATIO: | PASS |
| "THE FOOL RATIO" (P/E TO GROWTH): | FAIL |
| AVERAGE SHARES OUTSTANDING: | PASS |
| SALES: | FAIL |
| DAILY DOLLAR VOLUME: | PASS |
| PRICE: | PASS |
| INCOME TAX PERCENTAGE: | PASS |
Detailed Analysis of USANA HEALTH SCIENCES, INC.
REGENERON PHARMACEUTICALS INC (REGN) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Motley Fool is 75% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases. The Company's marketed products include EYLEA (aflibercept) Injection, Praluent (alirocumab) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use, Kevzara (sarilumab) Solution for Subcutaneous Injection and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. As of December 31, 2016, the Company had 16 product candidates in clinical development, which consisted of a Trap-based clinical program and 15 fully human monoclonal antibody product candidates.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
| PROFIT MARGIN: | PASS |
| RELATIVE STRENGTH: | PASS |
| COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: | PASS |
| INSIDER HOLDINGS: | PASS |
| CASH FLOW FROM OPERATIONS: | PASS |
| PROFIT MARGIN CONSISTENCY: | PASS |
| R&D AS A PERCENTAGE OF SALES: | PASS |
| CASH AND CASH EQUIVALENTS: | PASS |
| INVENTORY TO SALES: | PASS |
| ACCOUNTS RECEIVABLE TO SALES: | PASS |
| LONG TERM DEBT/EQUITY RATIO: | FAIL |
| "THE FOOL RATIO" (P/E TO GROWTH): | FAIL |
| AVERAGE SHARES OUTSTANDING: | FAIL |
| SALES: | FAIL |
| DAILY DOLLAR VOLUME: | FAIL |
| PRICE: | PASS |
| INCOME TAX PERCENTAGE: | FAIL |
Detailed Analysis of REGENERON PHARMACEUTICALS INC
More details on Validea's Motley Fool strategy
About Motley Fool: Brothers David and Tom Gardner often wear funny hats in public appearances, but they're hardly fools -- at least not the kind whose advice you should readily dismiss. The Gardners are the founders of the popular Motley Fool web site, which offers frank and often irreverent commentary on investing, the stock market, and personal finance. The Gardners' "Fool" really is a multi-media endeavor, offering not only its web content but also several books written by the brothers, a weekly syndicated newspaper column, and subscription newsletter services.
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
